1. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патологические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-153
2. Шишкин АН. Современные проблемы уремической кардиопатии. Нефрология 2003; 7(1): 14-20
3. McMahon AC, Greenwald SE, Dodd SM et al. Prolonged calcium transient and myocardial remodeling in early experimental uremia. Nephr Dial Transplant 2002; 17(5): 759-7642
4. Кутырина ИМ, Руденко ТЕ, Швецов МЮ, Кушнир ВВ. Факторы риска сердечно-сосудистых осложнений у больных на додиализной стадии хронической почечной недостаточности. Тер арх 2006; 5: 45-50
5. Сторожаков ГИ, Гендлин ГЕ, Томилина НА и др. Поражение сердечно-сосудистой системы при хронической почечной недостаточности. Рос Мед Журнал 2005; 2: 4-8
6. Смирнов АВ, Добронравов ВА, Румянцев АШ и др. Факторы риска ИБС у больных, получающих лечение гемодиализом. Нефрология 2003; 7(приложение 1): 7-13
7. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Advanc renal replacement ther 1997; 4(3): 2212-2246
8. Ishikawa M, Akishita M, Kozaki K et al. Amino-terminal fragment (1-34) of PTH inhibits migration and proliferation of cultured vascular smooth muscle cells. Atherosclerosis 1998; 136(1): 59-66
9. Qing DP, Ding H, Vadgama J et al. Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1-stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol 1999; 19(1): 84-92
10. Dhein S, Rohnert P, Markau S. Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Col Cardiol 2000; 36(2): 608-617
11. Hatori N, Havu N, Hofman-Bang C et al. Myocardial morphology and cardiac function in rats with renal failure. Jap Circ J 2000; 64(8): 606-610
12. Cortassa S, Aon MA, Marban E. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J 2003; 84(4): 2734-2755
13. Norris K, Vaughn C. The role of renin-angiotensin-aldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1(1): 51-63
14. Epstain M. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001; 40(7): 573-583
15. Duprez D, de Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2; 327-334
16. Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522
17. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14(9): 2253-2255
18. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1246
19. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001; 94(8): 378-383
20. Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap 2004; 124(2): 101-109
21. Oberleithner H, Ludwig T, Iethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43(5): 952-957
22. Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol 2004; 286(6): F1059-F1062
23. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbility and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
24. Gross F, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anutic hemodyalysis patients. Am J Kidney Dis 2005; 46(1): 94-101
25. Harris C, Meyer T, Brenner BM. Nephron ablation to renal injury. The Kidney. Eds. Brenner BM, Rector FC. Philadelphia, London, Tokyo 1986; 1555-1565
26. Okoshi K, Ribero HB, Okoshi MP et al. Improved systolic ventricular function with normal myocardial mechanics in compensated cardiac hypertrophy. Jpn Heart J 2004; 45(4): 647-656
27. Sevilla M, Voces F, Carron R et al. Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawl. Life Sci 2004; 75(2): 881-891
28. Rocha R, Martin-Berger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836
29. Barr CS, Lang CC, Hanson J et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseases. Am J Cardiol 1995; 76: 1259-1265
30. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16(2): 85-94
31. Rocha R, Stier CTJ, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878
32. Struthers AD. Aldosterone an important mediator of cardiac remodeling in heart failure. Br J Cardiol 2005; 12(3): 211-218
33. Connell JCM, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20.
34. Cases A, Bragulat E, Serradell M et al. Endothelial dysfunction in chronic renal failure. Nephrologia 2003; 23(4): 42-51.
35. Weber KT. Targeting pathological remodeling. Concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-1345